MaxioCel Solution MS100

Cambridge, MA, United States

Axio Biosolutions is a pioneering MedTech company dedicated to redefining emergency and advanced wound care through innovation and biotechnology. With a presence in 40+ countries, Axio develops next-generation solutions that save lives and improve patient outcomes across trauma, surgery, and chronic wound management. Axiostat® – Advanced Hemostatic Dressing (PBT Technology) is a breakthrough hemostatic dressing powered by Protonated Bioadhesive Technology (PBT) . Designed to instantly control moderate to severe bleeding in trauma, emergency, and surgical situations, Axiostat® creates a strong bioadhesive seal at the wound site, reducing blood loss and stabilizing patients in critical conditions. Trusted by armed forces, paramedics, and hospitals worldwide, Axiostat® is CE-certified, US FDA-cleared, ISO 13485 compliant, and NSN (NATO Stock Number) codified , ensuring global acceptance and standardization for defense and civilian use. MaxioCel® – Advanced Wound Dressing (BMG Technology) is an innovative wound dressing powered by Bioactive Microfiber Gelling (BMG) Technology for effective management of chronic and complex wounds, including diabetic foot ulcers, pressure ulcers, burns, and post-surgical wounds. Its unique gelling action provides superior exudate absorption, pain relief, and moist wound healing , supporting faster wound closure and enhanced patient comfort. MaxioCel® is CE-certified and ISO 13485 compliant , meeting the highest international standards in wound care. At Axio, we are driven by the mission to make world-class wound care accessible globally , blending cutting-edge science with compassionate healthcare. With strong regulatory certifications, NSN codification, and proven clinical outcomes, our portfolio continues to expand, addressing unmet needs in bleeding control and wound management, and setting new benchmarks in MedTech innovation.